Linzess denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for linzess are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Linzess as Duplicate Therapy

Aetna's duplicate-therapy denial for Linzess (linaclotide) typically means the reviewer identified another medication on your active medication list — most often another prescription agent used for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) — and concluded that both drugs serve the same clinical function. This denial is frequently based on a surface-level comparison of drug class rather than a clinical evaluation of how the two agents work or whether the existing therapy has actually been effective for you.

## Why This Denial Is Appealable

Linzess works through a distinct mechanism of action compared to other constipation treatments including osmotic laxatives, stimulant laxatives, and fiber supplements. If the "duplicate" Aetna identified is a different drug class or a therapy that has already been tried and found inadequate, the clinical distinction is a strong basis for appeal. Your prescriber's letter should explain specifically why the existing therapy is not clinically interchangeable with Linzess for your individual case — whether because of documented inadequate response, intolerability, or a clinically meaningful mechanistic difference.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial Explanation of Benefits (commonly 180 days for ERISA plans). Under ERISA §503 and ACA §2719, you are entitled to a full and fair review.
• External review: If the internal appeal is denied, request independent external review under ACA §2719. The standard window is approximately 4 months from the final internal denial notice; confirm the exact deadline on your denial letter.
• Expedited option: If your condition creates urgent clinical need, request expedited review at both stages.

## Documentation to Gather

1. Diagnosis confirmation — clinical notes, colonoscopy or imaging results, and symptom assessments establishing your IBS-C or CIC diagnosis. 2. Prior-treatment history — a dated, outcome-specific log of every constipation treatment previously tried, including prescription and over-the-counter agents, with documented durations and reasons for discontinuation or inadequate response. 3. Current therapy failure or intolerance — specific chart documentation showing the therapy Aetna considers a duplicate has not produced adequate clinical response or has caused intolerable side effects. 4. Prescriber medical-necessity letter — must directly address the duplicate-therapy finding by explaining the clinical distinction between Linzess and the therapy Aetna identified, and explaining why continued use of the latter is not an adequate alternative. 5. FDA-approved labeling — the Linzess prescribing information confirms its approved indications; reference this to confirm your use is within cleared indications.

## Criteria-Mapping Structure

Obtain Aetna's published coverage policy for Linzess and its duplicate-therapy criteria. Identify the specific drug Aetna called a duplicate. Then map each of Aetna's criteria to your chart: prior therapy tried (date, duration, outcome), documented inadequate response, prescriber's mechanistic rationale, and diagnosis confirmation. The clearer and more direct this mapping, the less discretion the reviewer has to sustain the denial.